TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Allergy Therapeutics ( (GB:AGY) ) is now available.
Allergy Therapeutics is exploring a dual primary listing on the Hong Kong Stock Exchange (HKEX) alongside its current listing on the London Stock Exchange’s AIM market. This move aims to expand the company’s presence in Asia, enhance trading liquidity, and broaden its investor base to include Hong Kong and mainland Chinese investors, aligning with its growth ambitions in the region.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Spark’s Take on GB:AGY Stock
According to Spark, TipRanks’ AI Analyst, GB:AGY is a Neutral.
The stock score is primarily impacted by the company’s weak financial performance and valuation concerns, which are somewhat balanced by positive technical indicators and promising corporate events. The financial instability remains a significant risk, although recent product developments offer potential upside.
To see Spark’s full report on GB:AGY stock, click here.
More about Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company based in the UK, specializing in the treatment and diagnosis of allergic disorders. The company markets proprietary and third-party products across nine major European countries and through distribution agreements in ten additional countries.
Average Trading Volume: 251,570
Technical Sentiment Signal: Buy
Current Market Cap: £519M
For a thorough assessment of AGY stock, go to TipRanks’ Stock Analysis page.